

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Croll-Kalish et al.

**Serial No.:** to be assigned                      **Group:** to be assigned

**Filing Date:** Concurrently Herewith      **Examiner:** to be assigned

**Title:** CIRL3-Like Proteins, Nucleic Acids, and Methods of Modulating  
CIRL3-L-Mediated Activity

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.


This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

**Fees**

No fee is required for the filing of this Information Disclosure Statement.  
If any additional fee should be deemed necessary, the Commissioner is hereby  
authorized to charge Deposit Account Number 18-0650.

Respectfully submitted

  
\_\_\_\_\_  
Valeta Gregg  
Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 1030A  
Serial No. : to be assigned  
Applicant: : Croll-Kalish  
Date Filed : Concurrently herewith  
For : CIRL3-LIKE PROTEINS, NUCLEIC  
ACIDS, AND METHODS OF  
MODULATING CIRL3-L-MEDIATED  
ACTIVITY

Examiner : Not Yet Known  
Group Art Unit : Not Yet Known

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner  
Initials

\_\_\_\_\_ NCBI, AAC77816, Calcium-independent alpha-latrotoxin receptor homolog 3 (Rattus norvegicus), J. Biol. Chem. 274 (9), 5491-5498 (1999).

\_\_\_\_\_ Bittner, M.A., et al., The Journal of Neurosciences, Vol. 18, No. 8, pp. 2914-2922, (1988).

\_\_\_\_\_ Krasnoperov, V.G., et al., Neuron, Vol. 18, pp. 925-937.

EXAMINER  
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

  
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400